Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Operating income | -$30.2M | -$41.2M | -$51.7M | -$75.9M | $1.85M | -$45.4M | -$25.2M | -$23.1M | -$21.8M | -$15.1M |
| Net income | -$31.0M | -$31.5M | -$50.2M | -$72.2M | $1.94M | -$49.9M | -$32.1M | -$30.0M | $1.44M | -$293M |
| EPS (diluted) | -$0.99 | -$0.83 | -$1.29 | -$1.85 | $0.05 | -$9.35 | -$6.01 | -$4.61 | $0.19 | -$34.67 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$25.7M | $3.09M | -$41.9M | -$43.4M | -$33.8M | -$24.6M | -$24.6M | -$14.8M | -$19.6M | -$13.5M |
| Capital expenditures | — | $52.4K | — | — | — | — | $16.3K | — | — | — |
| Free cash flow | — | $3.04M | — | — | — | — | -$24.7M | — | — | — |
| Share buybacks | — | $389.00 | — | — | — | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $83.0M | $26.1M | $50.2M | $21.4M | $25.4M | $60.8M | $36.1M | $40.9M | $21.4M | $82.3M |
| Total assets | $133M | $184M | $139M | $77.5M | $57.6M | $77.1M | $55.1M | $56.9M | $37.1M | $98.0M |
| Total liabilities | $27.0M | $52.1M | $48.9M | $49.7M | $4.96M | $69.1M | $75.1M | $85.4M | $62.8M | $234M |
| Shareholders' equity | $106M | $132M | $90.3M | $27.8M | $52.7M | $7.98M | -$20.0M | -$28.5M | -$25.7M | -$141M |
| Retained earnings | -$133M | -$164M | -$215M | -$287M | -$285M | -$335M | -$367M | -$397M | -$395M | -$689M |
| Shares (wtd avg diluted) | 35.0M | 38.7M | 38.9M | 39.0M | 40.9M | 5.34M | 5.34M | 6.51M | 7.57M | 8.46M |
Every figure is extracted from Minerva Neurosciences, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.